Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

zed, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. Once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations.

"The clinical trial will be conducted at multiple cancer centers in the United States," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "The clinical trial sites will include The University of Texas M.D. Anderson Cancer Center in Houston, Texas; the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Hematology Oncology Services of Little Rock, Arkansas."

LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About LX1032

LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition. In preclinical studies, LX1032 reduced peripheral serotonin and urinary 5-HIAA levels in several different species without affecting serotonin levels in the brain. In Phase 1 clinical studies, LX1032 reduced serotonin levels and urinary 5-HIAA in healthy volunteers consistent with preclinical results. LX1032 is being developed for the treatment of gastrointestinal symptoms associated with carcinoid syndrome in patients who
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 ActiGraph, a ... solutions for the global research community, announced today that ... Board. Dr. Matsudo is the Scientific Director of the ... (CELAFISCS), a Professor of Medicine at Gama Filho University ... organized by the State Secretariat of Health of São ...
(Date:6/18/2013)... June 18, 2013 Kitware , ... announces a new Fast-Track award from the U.S. Department ... environment (IDAE) for the nuclear power industry. , Construction ... more than 30 years, but the United States’ nuclear ... gains in power plant utilization through improved refueling, maintenance, ...
(Date:6/17/2013)... As a leader in the skincare industry, the team ... for acne, rosacea, and eczema. As part of Acne and ... Rosacea Society) has dedicated a month to creating awareness about ... on treatment options. Probiotic Action follows in the footsteps of ... via social networks and online resources for the acne and ...
(Date:6/17/2013)... and BOSTON , June 17, ... is set to reach $127 billion by 2018, accounting for ... the recently released Orphan Drug Report 2013 from ... clients, needs in regard to this growing segment of the ... product database to include in-depth, fact-based orphan drug analysis with ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3
... ) today reported results for the third quarter ended September,30, ... per share, for,the third quarter 2007, from a net loss ... 2006. Cash and short-term investments totaled,$13.9 million at September 30, ... quarter 2007 is due to a 21%,decrease in operating expenses ...
... Reports Results for the Nine Month Period Ended September ... ... results for the nine month period ended September 30, 2007,as follows: Revenues ... September 30, 2007. In the same period of 2006, Genmab,recognised DKK 105.6 million ...
... ANN ARBOR, Mich., Oct. 30 NanoBio(R) ... commercializing novel,products for the prevention and treatment ... Joyce Sutcliffe, Ph.D., as vice president of,research. ... in the discovery and design of,new antibiotics, ...
Cached Biology Technology:Pharmos Corporation Reports 2007 Third Quarter Results 2Pharmos Corporation Reports 2007 Third Quarter Results 3Pharmos Corporation Reports 2007 Third Quarter Results 4Pharmos Corporation Reports 2007 Third Quarter Results 5Genmab Announces Results for the First Nine Months of 2007 2Genmab Announces Results for the First Nine Months of 2007 3Genmab Announces Results for the First Nine Months of 2007 4Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research 2
(Date:6/17/2013)... and a major cause is a deadly fungus thought ... shows they can also die from this pathogen, contrary ... that just spreads the disease. , When researchers raised ... found at least one strain of this pathogen, ... fungus, can be fatal to year-old juveniles. However, bullfrogs ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
(Date:6/16/2013)... A "cold snap" 116 million years ago triggered a ... past as a result of global warming, according to ... international study involving experts from the universities of Newcastle, ... global cooling and a crash in the marine ecosystem ... quantifies for the first time the amplitude and duration ...
Breaking Biology News(10 mins):Bullfrogs may help spread deadly amphibian fungus, but also die from it 2HIV prevention among female sex workers in India reduces HIV and syphilis 2Global cooling as significant as global warming 2
... recently received two grants from the National Science ... on the Implications of Cutting-Edge Biotechnologies for Sustainability ... research on the use of on-line prediction markets ... The workshop will develop an EU-U.S. trans-disciplinary research ...
... Joseph, Michigan A new internet-based tool for designing ... and to optimize design by allowing rapid development of ... of Resource: Engineering & Technology for a Sustainable ... and Agricultural Engineering at the University of Missouri, introduces ...
... investigation an international body of earth scientists has formally agreed ... by 800,000 years, reports the Journal of Quaternary Science ... International Commission on Stratigraphy (ICS), the authority for geological science ... declaring when the Quaternary Period, which covers both the ice ...
Cached Biology News:Web-based innovation improves, eases agricultural terrace design 2End of an era: New ruling decides the boundaries of Earth's history 2
... peptide derived from the C-terminal region of ... D iris-expressed growth factor spinal cord-derived growth ... rat by one amino acid replacement. ... mouse and rat PDGF-D proteins. Reactivity: ...
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
...
... 100% ,human IgG subclass 2 ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... IgG Fab ...
Biology Products: